ViTToria Biotherapeutics, Inc. — Cyborg Score 7/10

Strategic Profile

The company's proprietary Senza5 platform improves the efficacy, safety, and utility of cell-based treatments. VIPER-101, a novel gene-edited autologous dual-population CAR-T therapy, dosed its first patient in a Phase 1 clinical trial in November 2024. The company is leveraging Philadelphia's emerging biotech ecosystem and deep expertise in cell therapy.

Cyborg Score Rationale

ViTToria demonstrates solid positioning in the high-growth gene-edited CAR-T cell therapy space with differentiated platform technology, experienced leadership, and clinical momentum. Risks include early-stage pipeline, competitive CAR-T landscape, and limited revenue generation, tempered by strong investor backing and orphan disease focus.

Top Insights

• VIPER-101 entered Phase 1 trials in November 2024, marking the company's transition to human dosing.
• The company has raised $35M to date, with over $15M secured in a recent private financing round.
• Backing includes Agent Capital, Tellus BioVentures, NYBC Ventures, Valley Forge Investment Corporation, and University of Pennsylvania.
• The company operates with approximately 15 employees.

Named Competitors

• Allogene Therapeutics — Off-the-shelf allogeneic CAR-T cell therapy platform
• Cidara Therapeutics — Cell therapy and immunotherapy development
• Lisata Therapeutics — CAR-T cell therapies for solid tumors and hematologic malignancies
• Amphivena Therapeutics — Engineered cell therapy platform

Recent Developments

• (November 2024) First patient dosed in Phase 1 clinical trial of VIPER-101 CAR-T therapy
• (Q4 2024) Secured over $15M in private financing round to advance CAR-T development
• (December 2024) Announced Phase 1 trial progress for VIPER-101 in T-cell lymphoma

Open the full interactive ViTToria Biotherapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.